ORCA Therapeutics is a pioneering brand dedicated to enhancing the lives of individuals battling prostate cancer. With a strong commitment to fighting this disease, they are focused on developing safe and highly potent oncolytic virus immunotherapies. As the second leading cause of cancer death in men, prostate cancer poses a significant challenge.

However, ORCA is determined to make a difference. Understanding the devastating impact of cancer on families, ORCA collaborates with top experts in the field to ensure their therapies are effective and impactful. Their lead compound, ORCA-010, is currently undergoing Phase I/IIa clinical testing in treatment naive patients with localized prostate cancer.

This study, conducted in Canada, has received approval for the second dose level cohort in the dose escalation phase. By tackling prostate cancer head-on, ORCA Therapeutics aims to provide hope and a brighter future for patients and their loved ones. Together, they strive to overcome this disease and eliminate its devastating consequences